NVCR - NovoCure: Sell The METIS-Inspired Rally

2024-03-27 22:55:50 ET

Summary

• NovoCure’s METIS trial met its primary endpoint but missed key secondary outcomes, casting doubt on TTFields' efficacy in NSCLC.
• Despite hitting the primary endpoint, TTFields’ role in NSCLC treatment is questionable without significant overall survival benefits.
• NovoCure's financial health shows a steady cash runway despite declining revenues and increasing net losses.
• Recommendation: Sell NovoCure stock due to underwhelming METIS data and financial deceleration, despite a 15% rally.

NovoCure's NSCLC Niche: A Market Mirage?

In the beginning of the year, I maintained a Sell recommendation for NovoCure ( NVCR ) following, what I believed were, lackluster clinical results and year over year revenue declines for its flagship product, Tumor Treating Fields (TTFields). I noted that NovoCure appears to have hit a ceiling in the glioblastoma market and the clinical trial results in other indications like NSCL and ovarian cancers were unconvincing and unlikely to boost future revenues....

For further details see: